Does US need another expedited development pathway? Groups weigh in
This article was originally published in Scrip
Executive Summary
US regulators got a mixed response on 4 February to a proposed new pathway aimed at expediting the development of medicines intended to treat serious or life-threatening conditions with unmet medical needs in which the FDA would permit manufacturers to take a streamlined approach with shorter studies using smaller patient populations.